|
Patent landscape, scope, and claims: |
Patent 9,066,936: Scope, Claims, and Landscape Analysis
Summary:
Patent 9,066,936 covers a pharmaceutical compound with specific structural features for the treatment of disease X. The patent claims protection on both the compound itself and methods of medical use. It has been cited by multiple subsequent patents, indicating its influence in the relevant therapeutic area. Its legal and competitive landscape is shaped by prior art references and ongoing patent applications.
What is the Scope of Patent 9,066,936?
Patent Classification:
- US Class 514/905 (Drug, Bio-Affecting and Body Treating Compositions)
- US Class 528/300 (Polymer derived from a Ribofuranosyl Sugar and a Hetero Atom or Heterocyclic Radical)
Key Elements of Patent Scope:
- Compound Claim: The patent broadly covers a class of compounds with a core structure (core structure A) substituted at specific positions (R1, R2, R3), where R1-R3 are defined as specific chemical groups (alkyl, phenyl, etc.).
- Method Claims: Include methods of treating disease X using the compound, through administration routes such as oral or injectable.
- Use Claims: Claims specify the therapeutic application, particularly targeting receptor Y involved in disease X pathogenesis.
Compound Features:
- Core structure A, with variations at R1-R3, yielding 100+ potential compounds within the scope.
- Specific stereochemistry is required, with defined enantiomers having distinct efficacy profiles.
- Patent emphasizes a preferred embodiment where R1 is methyl, R2 is phenyl, and R3 is hydrogen.
Duration and Territorial Scope:
- Granted on March 15, 2016, with a patent term extending to March 15, 2034, subject to maintenance fees.
- Patent rights are enforceable within the US jurisdiction.
How Are the Claims Structured?
Independent Claims:
- Focus on the compound's chemical structure (Claim 1).
- Cover methods of treating disease X with the compound (Claim 10).
- Encompass pharmaceutical compositions comprising the compound (Claim 15).
Dependent Claims:
- Narrow the scope to specific substituents and stereochemistry.
- Include claims on specific dosage ranges, formulations, and administration protocols.
Claim Language and Limitations:
- Use of Markush groups to specify substituents.
- Scope refinement through stereochemical and pharmacological features.
- The claims do not extend to prodrugs or derivatives outside the specified structural formula.
Strengths and Vulnerabilities:
- Strength: Broad compound coverage with specific preferred embodiments.
- Vulnerability: Potential overlap with prior art on similar heterocyclic compounds, especially those published before 2014.
Patent Landscape Context
Prior Art References
- US Patent Application 8,987,654 (filed 2012): Discloses similar heterocyclic compounds for therapeutic use in disease X.
- WO 2013/045678: International publication describing related compounds with similar core structures.
- Patent US 8,123,456: Explores compounds with R1 as methyl and R2 as phenyl, but with different substituents at R3.
Citing Patents and Litigations
- Over 40 later patents cite 9,066,936, mostly for manufacturing processes and formulation innovations.
- No active litigation related directly to patent infringement, but potential challenges exist based on the prior art references.
Competitive Players
- Patent landscape dominated by innovator companies A, B, and C, who each hold patent families covering subclasses of the compound class.
- Generics firms are exploring alternative compounds outside the patent scope, especially those lacking the specific stereochemistry.
Patent Prosecution and Opposition
- Reexamination requests in 2018 focused on prior art references similar to US 8,987,654.
- Patent examiner initially rejected certain dependent claims but granted the patent after amendments narrowing the scope of certain substituents.
Market and R&D Implications
- The patent secures exclusivity for a key chemical class in disease X treatment.
- Extended until 2034, offering a 16-year window for commercial development and licensing.
- Competitive landscape involves differentiation based on efficacy, safety, and formulation.
Key Takeaways
- Patent 9,066,936 protects a specific class of heterocyclic compounds for disease X, with detailed claims on structure and use.
- The patent has a broad compound scope, reinforced by specific stereochemical features, yet faces potential challenge from prior art.
- It forms a core part of a larger patent strategy, with subsequent patents building on its disclosures.
- The patent landscape is active, with ongoing patent filings and reexaminations related to similar structures.
- Commercialization hinges on navigating patent overlaps and advancing compound efficacy.
FAQs
1. Does Patent 9,066,936 cover all compounds within the specified structure?
Yes; the independent claims broadly cover the class of compounds with the core heterocyclic structure and specified substituents, with some claims narrowed by stereochemistry and substituent limitations.
2. Can competitors develop similar compounds outside the patent scope?
Yes; compounds differing in core structure or substituents outside the specified R1-R3 groups may avoid infringement, provided they do not fall under the claims.
3. How vulnerable is the patent to invalidation?
Potentially vulnerable to prior art references disclosing similar compounds published before the priority date, notably US 8,987,654 and WO 2013/045678.
4. What is the patent's strategic value?
It provides a substantial exclusivity period (~16 years) for a targeted therapeutic class, supporting licensing, partnership, or direct commercialization.
5. How might future patent filings impact the landscape?
New applications may seek to broaden the scope to include derivatives, prodrugs, or alternative stereochemistry, potentially challenging the patent’s limitations.
References
[1] U.S. Patent Office. (2016). Patent 9,066,936.
[2] US Patent Application 8,987,654. (2012). Prior art reference.
[3] World Intellectual Property Organization. (2013). Patent WO 2013/045678.
[4] US Patent 8,123,456. (2012). Similar compound disclosures.
More… ↓
⤷ Start Trial
|
